ARASENS: Darolutamide + ADT + Docetaxel may become new SOC for mHSPC - from ASCO GU Symposium 2022

[JRPnSD]

Dr. Matthew R Smith of Mass Gen. CC, reported significant overall survival from 3 ARASENS trial results when compared to placebo + ADT + Docetaxel. A 32% reduction in the risk of death with no increased toxicity (pub. in NEJofM and wrap-up edition of ASCO GU 2022 Symposium). With such dramatic results, when might we see adoption as SOC?

[JRPnSD]

I am already far down the road of my treatment. Hopefully, this is good news for someone starting their journey.

[Hidden in reply to JRPnSD]

Ok .Thanks

[CAMPSOUPS]

Interesting. PEACE-1 --ADT, Dox chemo, and Abiraterone.

ARASENS--ADT, Dox chemo, and Darolutamide.

[JRPnSD in reply to CAMPSOUPS]

Results from Peace 1?

[MateoBeach]

Should already be SOC for de novo mHSPC. That is the optimum, highest stand of care. The “gold standard” etc. Not “standard care”, some prior and lesser care such as ADT alone in that specific circumstance. Now we need to see if it is applicable at some later circumstance, such as newly metastatic at BCR after primary treatment, but without prior ADT. On with further trials.

[JRPnSD in reply to MateoBeach]

Good to know. Not having a new diagnosis, this is little help to me, but hopefully, this post helps get the word out. I find a great difference in cancer patient care if you are not at a major cancer center for your treatment.